BEA TECHNOLOGIES S.p.A.

CONSTANT INNOVATION: BEA Technologies is a leader in the production of filter elements with high capacity and membranes for the purification of chemical-pharmaceutical products, liquid and viscous products.

In the field of filtration and purification for pharmaceutical applications, BEA Technologies, an Italian company with a consistent international network, has a consistent experience in the production of customized filters and products as the membrane filters in NYLON 66 with positive charge to retain Endotoxins.

BEA Technologies, an Italian company with a consistent international presence, is one of  the leaders in Europe in the production of membrane filters and filters with nanofibers for the filtration of liquid solutions and "critical" products as the NYLON 66 – positive charged membrane filters.

The company is able to offer the most suitable products for the solution of a wide range of specific filtration problems, which can also be customized on the basis of the most challenging customer needs. Among the proposed filtration solutions, high-performance filtration systems for the pharmaceutical sector have been developed, in particular the line of filter elements POSINYL that are made with positive charged NYLON 66 membranes with high capacity to retain endotoxins and POSITRAK for very fine particles.


The Italian company meets the demands of the pharmaceutical sector: “We offer a series of filters, specific for pharmaceutical applications”, declares Mr. Roberto Bea, President of BEA Technologies, who considers Research and Development processes as the key to success. “Our purpose is to become a leader of the European market in the supply of filtration products specific for this sector; our efforts are dedicated to design new filters to satisfy the request of our pharmaceutical customers and to be recognized as significant players worldwide.”

Among the solutions proposed by the company, which in recent years has focused on the application of Positive charged filters and nanofibers for the pharmaceutical industry, new high-performance filtration systems and products are announced.


BEA Technologies offers three series of filter elements with nanofibers called MAGNEX, NANOTRAK and NOVATRAK, that meet the needs of companies engaged in the production of new generation drugs (which have a high degree of sensitivity during the production process).


For the purification of viscous products and solutions (as gelatine based products) BEA Technologies has developed the MAGNEXFLO automatic filtration system which can retain even small particles and make the solution very clear and ready to be used for additional process steps. The scope is to ensure optimal automatic filtration in demanding situations as the purification of "critical" or viscous products.

In addition, for specific pharma processes, which are not permitting the presence of “animal substance”, we are producing the BEAPURE series of “ANIMAL-FREE” which are assembled using “animal-free” certified materials and polymers (besides the BSE/TSE safety requirements) to guarantee any possibility of contact between the pharma products with tallow-derived additives, often present in various polymers.

Critical microfiltration products are produced in a controlled atmosphere environment (clean room) and in compliance with the GMP guidelines, to ensure a high level of quality and cleanliness for biological applications.

“In 1981, we were one of the first companies in Italy to install a clean room for the production of filter elements", says Mr. Roberto Bea. “Of course, the cleanroom has been constantly adapted to the changing needs; the last major innovation in 2011, when we completed the expansion and modernization of the production spaces and a new expansion of production capacity is planned for 2024. We believe that filtration processes are increasingly essential to ensure the high quality of products on the market"

Discover more on www.bea-italy.com

Bea Technologies Spa

Phone +39 02 339 271  |  Fax +39 02 339 0713  |  info@bea-italy.com  |  www.bea-italy.com

Phone +39 02 339 271  |  Fax +39 02 339 0713
info@bea-italy.com  |  www.bea-italy.com

10/10/2024 10:15:19
  • Home | Enhancing therapy adherence with prodrugs
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Cytiva
  • Nipro
  • Laboratorios Argenol Company Insight
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Project Updates
  • Avenga Company Insight
  • Lactalis Ingredients
  • BSP Pharmaceuticals
  • AlfatestLAB
  • Alphial Company Insight
  • In Depth
  • Prodrugs and patents: Enhancing therapy adherence and reducing side effects
  • Are PBMs to blame for high drug prices in the US?
  • Into the unknown: how quickly can vaccines be developed for Disease X
  • US negotiations for first round of drugs reveal $6bn in Medicare savings
  • Emerging microbiome market – unlocking new frontiers
  • Build or buy? Key considerations for in-house manufacturing
  • BiomeBank Company Insight
  • IMP Pharmaceutical Services
  • Xylem
  • Sponsored Supplements
  • Techniconsult Firenze Company Insight
  • Pfanstiehl
  • Duoject Medical Systems Company Insight
  • Listings
  • Events
  • Excellence Awards
  • Innovation Rankings
  • Buyer's Guides
  • Zenatek Company Insight
  • BEA Technologies
  • Next issue
09/20/2024 00:00:00